長沼 誠 (ナガヌマ マコト)

Naganuma, Makoto

写真a

所属(所属キャンパス)

医学部 内科学教室(消化器) (信濃町)

職名

准教授

経歴 【 表示 / 非表示

  • 2003年01月
    -
    2006年05月

    Department of Gastroenterology, School of Medicine, University of Virginia

  • 2006年06月
    -
    2006年10月

    慶應義塾大学医学部 内科学, 臨床助手

  • 2006年11月
    -
    2009年05月

    慶應義塾大学医学部 日清キョーリン・旭化成メディカル寄附講座, 講師

  • 2009年06月
    -
    2011年12月

    東京医科歯科大学大学院医歯学総合研究科 消化管先端治療学講座, 講師

  • 2012年01月
    -
    2015年05月

    慶應義塾大学医学部 内視鏡センター, 助教 専任講師

全件表示 >>

学歴 【 表示 / 非表示

  • 1992年03月

    慶應義塾大学, 医学部

    日本, 大学, 卒業

学位 【 表示 / 非表示

  • 医学博士, 慶應義塾, 論文, 2003年02月

    Characterization of strictures with T-lymphocyte aggregate in ileal villi of Crohn’s disease.

免許・資格 【 表示 / 非表示

  • 医師免許, 1992年05月

  • 日本消化器病学会専門医, 2000年01月

  • 日本消化器内視鏡学会専門医, 2001年01月

  • 日本消化器内視鏡学会専門医, 2001年01月

  • 日本医師会産業認定医, 2002年09月

全件表示 >>

 

研究分野 【 表示 / 非表示

  • 消化器内科学

研究キーワード 【 表示 / 非表示

  • 大腸肛門病学

  • 消化器内視鏡

  • 炎症性腸疾患

 

著書 【 表示 / 非表示

  • Therapeutic Endoscopy. Kim WH, Cheon JH editors Atlas of inflammatory bowel diseases.

    長沼 誠, Springer (Germany), 2015年

  • New endoscopic modalities in IBD. Kim WH, Cheon JH editors Atlas of inflammatory bowel diseases.

    長沼 誠, Springer (Germany), 2015年

論文 【 表示 / 非表示

  • Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients

    Mutaguchi M., Naganuma M., Sugimoto S., Fukuda T., Nanki K., Mizuno S., Hosoe N., Shimoda M., Ogata H., Iwao Y., Kanai T.

    Digestive and Liver Disease (Digestive and Liver Disease)  51 ( 9 ) 1257 - 1264 2019年09月

    ISSN  15908658

     概要を見る

    © 2019 Editrice Gastroenterologica Italiana S.r.l. Background: Although various studies have been conducted on colitis-associated cancer (CAC), few have assessed the differences in the clinical and endoscopic features, treatment, and prognosis of CAC and sporadic neoplasia (SN) in the inflamed mucosa of ulcerative colitis (UC) patients. Aims: To compare the characteristics of CAC and SN within the previously or currently inflamed mucosa. Methods: Between 1997 and 2017, we retrospectively analyzed the endoscopic chart data of 348 colonic lesions from 266 UC patients. Non-dysplastic lesions and lesions located outside the inflamed mucosa were excluded. The diagnosis of CAC or SN was confirmed by conventional histopathological and immunohistochemical evaluation of p53 and Ki67. Results: In total, 74 patients with CAC (97 lesions) and 46 with SN (58) were enrolled. The proportions of patients with a younger age of onset of UC, with chronic persistent UC, and with severe inflamed mucosa were significantly higher in the CAC group. In the SN group, no flat lesions were found, whereas 26% of the lesions in the CAC group were flat. Sixteen patients died during a median follow-up of 6.1 years (interquartile range (IQR) 1.8–11.1)in the CAC group, whereas 1 patient died during a median follow-up 3.2 years(IQR 1.4–4.6) in the SN group. Mortality from colorectal cancer was significantly higher (P = 0.015) in the CAC group (12/68; 17.6%) than in the SN group (1/44; 2.3%). The 5-year survival rate was 100% in the SN group and 97% in the CAC group for lesions located in the mucosa or submucosa. Conclusion: Recognizing differences in the characteristics of CAC and SN within the inflamed mucosa is critical to avoid unnecessary total colectomy in patients with SN.

  • Management of elderly ulcerative colitis in Japan

    Higashiyama M., Sugita A., Koganei K., Wanatabe K., Yokoyama Y., Uchino M., Nagahori M., Naganuma M., Bamba S., Kato S., Takeuchi K., Omori T., Takagi T., Matsumoto S., Nagasaka M., Sagami S., Kitamura K., Katsurada T., Sugimoto K., Takatsu N., Saruta M., Sakurai T., Watanabe K., Nakamura S., Suzuki Y., Hokari R.

    Journal of Gastroenterology (Journal of Gastroenterology)  54 ( 7 ) 571 - 586 2019年07月

    ISSN  09441174

     概要を見る

    © 2019, Japanese Society of Gastroenterology. Japan has the largest aging society, where many elderly people have intractable diseases including ulcerative colitis (UC). Along with the increasing total number of UC patients, the number of elderly UC patients has also been increasing and will continue to do so in the future. Although the clinical features and natural history of UC in the elderly have many similarities with UC in the non-elderly population, age-specific concerns including comorbidities, immunological dysfunction, and polypharmacy make the diagnosis and management of elderly UC challenging compared to UC in non-elderly patients. Based on increasing data related to elderly UC patients from Japan, as well as other countries, we reviewed the epidemiology, clinical course, differential diagnosis, management of comorbidities, surveillance, medical therapy, and surgery of UC in the elderly.

  • How Can We Assess "Complete Healing" Beyond Endoscopic Remission?

    Fukuda T., Naganuma M., Kanai T.

    Inflammatory bowel diseases (Inflammatory bowel diseases)  25 ( 6 )  2019年05月

  • Treatment with indigo naturalis for inflammatory bowel disease and other immune diseases

    Naganuma M.

    Immunological Medicine (Immunological Medicine)  42 ( 1 ) 16 - 21 2019年01月

     概要を見る

    © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the Japanese Society of Clinical Immunology. Indigo naturalis (IN) is a herbal medicine extracted from leaves and stems of plants and is a component of crude drugs used in China. Recently, IN was reported to be effective for treating (UC) and psoriasis. The mechanisms of IN for UC is not clear, but aryl hydrocarbon receptor ligand, the active components of IN, can promote mucosal healing by inducing the production of interleukin-22 from type-3 innate lymphocytes cells. Although IN is effective even for refractory cases, critical adverse effects including IN-induced colitis and pulmonary arterial hypertension should be concerned. Due to adverse effects of IN, topical treatment of IN is useful for distal UC as well as psoriasis to secure patients’ safeties. Many refractory patients may be helped by IN if it becomes available in appropriate forms for clinical practice. In the near future, the mechanism that underlies the adverse effects of IN needs to be determined, and extraction of active ingredients with fewer side effects, investigated.

  • Current new challenges in the management of ulcerative colitis

    Fukuda T., Naganuma M., Kanai T.

    Intestinal Research (Intestinal Research)  17 ( 1 ) 36 - 44 2019年01月

    ISSN  15989100

     概要を見る

    © 2019, Korean Association for the Study of Intestinal Diseases. All rights reserved. Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract. Although the cause of UC is postulated to be multifactorial in nature, including genetic predisposition, epithelial barrier defects, dysregulation of immune responses, and environmental factors, the specific pathogenesis of UC is still incompletely understood. In the treatment of UC so far, a method of suppressing immunity and treating it has been mainstream. Immunosuppressant drugs, including thiopurines (azathioprine or 6-mercaptopurine), anti-tumor necrosis factor-α (anti-TNF-α) antibody (infliximab and adalimumab), and calcineurin inhibitor, can be used in treat patients with corticosteroid-dependent and/or corticosteroid-refractory moderateto-severe UC. Recently, in addition to such a conventional therapeutic agent, golimumab, which is the first transgenic human monoclonal anti-TNF-α antibody to be fabricated, anti α-4/β-7 integrin antibody, and Janus kinase inhibitor have been reported to novel immunosuppressant therapy. Furthermore, other treatments with unique mechanisms different from immunosuppression, have also been suggested, including fecal microbiota transplantation and Indigo naturalis, which is a Chinese herbal medicine. We compared the features and efficacy of these new treatments. In this issue, the features and treatment options for these new treatments is reviewed.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

競争的資金等の研究課題 【 表示 / 非表示

  • 治療最適化を目指した潰瘍性大腸炎患者の腸内細菌・口腔内細菌叢の解析

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 長沼 誠, 基盤研究(C), 補助金,  代表

  • インドール含有青黛生薬の炎症制御機序解明および大腸癌抑制効果の検証

    2016年04月
    -
    2019年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 長沼 誠, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • 第27回日本消化器病学会奨励賞

    2014年

  • 第27回日本消化器病学会奨励賞

    2014年

  • 第172回FALKシンポジウム 優秀ポスター演題受賞

    2010年

  • 第12回国際粘膜免疫学会(ICMI)若手研究賞

    2005年

  • Gastrointestinal Response to Injury若手研究賞

    2004年

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 消化器内科学臨床実習

    2019年度

  • 内科学(消化器)講義

    2019年度

担当経験のある授業科目 【 表示 / 非表示

  • 内科学系統講義(消化器内科)

    慶應義塾, 2018年度, 通年, 専門科目, 講義

  • 内科学(消化器内科)

    慶應義塾大学医学部, 2018年度

 

所属学協会 【 表示 / 非表示

  • 日本内科学会

     
  • 日本消化器病学会

     
  • 日本消化器内視鏡学会

     
  • 日本大腸肛門病学会

     
  • 日本消化管学会

     

全件表示 >>

委員歴 【 表示 / 非表示

  • 2018年08月
    -
    継続中

    教育委員会委員長, 日本炎症性腸疾患学会

  • 2017年10月
    -
    継続中

    ガイドライン作成委員, 日本アフェレーシス学会

  • 2017年
    -
    継続中

    Epidemiology committee member, Asian Organization of Crohn’s and Colitis

  • 2016年10月
    -
    継続中

    機関誌編集委員, 日本消化器病学会

  • 2012年06月
    -
    継続中

    東京難病認定審査会審査委員, 東京都

全件表示 >>